2010-01-30
needs context
speaker_own · asserts · email
In Europe, this pathway to use of adjuvant through their regulatory agency permitted the use of adjuvants in influenza vaccine, so what is the reason that the U.S. cannot seem to provide a reasonable pathway to accomplish a similar allowance ?
Reading Room Production, p.450 · original PDF · in context